Ultragenyx Pharmaceutical (RARE) Net Cash Flow Growth (3y) (2016 - 2026)
Ultragenyx Pharmaceutical (RARE) Net Cash Flow Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Ultragenyx Pharmaceutical | 2.71 Bn | 2.30 Bn | 106.00 Mn | -74.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -74.51% |
| Dec 31, 2025 | 41.85% |
| Sep 30, 2025 | -52.12% |
| Jun 30, 2025 | 81.03% |
| Mar 31, 2025 | 33.12% |
| Dec 31, 2024 | -36.16% |
| Sep 30, 2024 | -52.81% |
| Jun 30, 2024 | 80.92% |
| Mar 31, 2024 | 33.60% |
| Dec 31, 2023 | -35.74% |
| Sep 30, 2023 | 41.08% |
| Jun 30, 2023 | -23.96% |
| Mar 31, 2023 | 29.95% |
| Dec 31, 2022 | -41.57% |
| Sep 30, 2022 | 211.81% |
| Jun 30, 2022 | 27.16% |
| Mar 31, 2022 | -43.88% |
| Dec 31, 2021 | 49.68% |
| Sep 30, 2021 | -49.25% |
| Jun 30, 2021 | 6.50% |